The latest biotech news

Arthrogen rheumatoid arthritis gene therapy

News and Trends 17 Feb 2017

Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials

Arthrogen will start a Phase Ib trial for a gene therapy aiming to treat rheumatoid arthritis with a single injection and reduce costs for patients. Arthrogen, based in Amsterdam, is developing local gene therapies for inflammatory diseases. The biotech company has now announced it has received approval to start a Phase Ib trial with its lead […]

February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Feb 2017

UPDATE: More Promising Results from Mologen’s New HIV Therapy

Update (17/02/2017): Mologen has announced more positive data for lefitolimod in HIV, as the Danish Aarhus University Hospital showed for the first time that the drug can induce a local antiviral immune response in patients undergoing ART. Definitive results are expected later this year. Originally published on 11/01/2017 Mologen’s partner in the development of an HIV therapy has […]

February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Feb 2017

UPDATE: British Biotech Investment Company goes Public with €117M

UPDATE (17/02/2017): Arix Bioscience announced that it has successfully raised £100M (€117) in an oversubscribed IPO on the London Stock Exchange. Originally published on 02/02/2017 Arix Bioscience is getting ready for an IPO that could reach up to €117M (£100M). The funds will be directed at small life science companies. Arix Bioscience is a ‘global healthcare and life […]

February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Antibiotic Resistance Queens University Belfast

News and Trends 16 Feb 2017

British Scientists Discover how Deadly Bacteria Survive a Last-Line Antibiotic

Researchers from the UK and Australia have described for the first time the detailed molecular mechanisms behind last-line antibiotic resistance. A month ago, the news of a woman who died of an infection with a bacteria resistant to all 26 antibiotics available in the US traveled the world. The bacterial strain responsible, Klebsiella pneumoniae, is one […]

February 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Feb 2017

The Patent Office has Spoken: What does it Mean for CRISPR in Europe?

The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […]

February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Feb 2017

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […]

February 15, 2017 - 3 minutesmins - By Melanie De Almeida

AlzProtect crowdfunding neurodegenerative disease

News and Trends 15 Feb 2017

French Biotech bids for Crowdfunding in Neurodegenerative Disease

AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […]

February 15, 2017 - 2 minutesmins - By External Contributor

News and Trends 15 Feb 2017

French Biotech gets a Boost in the NASH Race with a Successful IPO

Inventiva has completed an IPO on Euronext Paris raising €48M that will support the advancement of its pipeline, which includes big indications such as NASH. Inventiva, a drug discovery company from France, is the protagonist today of a successful biotech IPO on Euronext Paris despite the financial difficulties of past years. The company has raised €48M, which will […]

February 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Feb 2017

Optogenetics: What Makes It a Powerful Neuroscience Tool?

It’s a brand-new field and possibilities seem infinite. Here’s what you need to know about its rapid development into a powerful genetic tool. What is Optogenetics? What if you could activate and deactivate neurons by simply switching on the lights? That’s the basis of optogenetics, the control of cell behavior via light-sensitive proteins. Optogenetics is a […]

February 15, 2017 - 3 minutesmins - By External Contributor

News and Trends 14 Feb 2017

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical development. The company Allergy Therapeutics is developing immunotherapeutic vaccines for the treatment of allergies and has been quite successful. Their Pollinex Quattro range of vaccines against […]

February 14, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 14 Feb 2017

Which European Country is Winning the Race in Clinical Development?

A report from the French Association of Biotechnology, France Biotech, could be alerting the French health-care sector this week. The report lists the top European countries leading in clinical development – with France clearly dragging behind other Western European countries. Based on data from the EU Clinical Trials Register, the data compiled by France Biotech reveals which countries are on […]

February 14, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 14 Feb 2017

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […]

February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Gene Therapy for Rheumatoid Arthritis gets Approval to Start Clinical Trials

UPDATE: More Promising Results from Mologen’s New HIV Therapy

UPDATE: British Biotech Investment Company goes Public with €117M

British Scientists Discover how Deadly Bacteria Survive a Last-Line Antibiotic

The Patent Office has Spoken: What does it Mean for CRISPR in Europe?

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

French Biotech bids for Crowdfunding in Neurodegenerative Disease

French Biotech gets a Boost in the NASH Race with a Successful IPO

Optogenetics: What Makes It a Powerful Neuroscience Tool?

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Which European Country is Winning the Race in Clinical Development?

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

Subscribe to our newsletter to get the latest biotech news!